9 in 10 Mantle Cell Lymphoma Patients Benefit from Calquence, AstraZeneca Reports
News
Calquence (acalabrutinib) eliminated tumors in 40 percent of mantle cell lymphoma patients who took part in a Phase 2 clinical trial, AstraZeneca and Acerta Pharma reported. An additional 41 percent in the ACE-LY-004 trial ... Read more